At meeting held on 16 April 2020
The Board of Cadila Healthcare has approved and signed the definitive agreement for sale of 9,44,233 equity shares of Rs. 10/- each fully paid-up, representing 2% of the total paid-up share capital of Windlas Healthcare, a subsidiary company to Windlas Biotech.Upon completion of the transaction in relation to the sale of the said equity shares, the total shareholding of the Company in WHPL will reduce to 49.00% (forty-nine percent) from 51.00% (fifty-one percent) and WHPL will cease to be the subsidiary of the Company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
